Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients

This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with conventional Transarterial Chemoembolization (TACE) for the treatment of patients with unresectable Hepatocellular Carcinoma (HCC).

NCT Number	NCT07321613
Lead Sponsor	Shanghai Zhongshan Hospital
Conditions	Hepatocellular Cancer (HCC)
Enrollment	545 participants
Start Date	2023-05-01
Primary Completion	2025-05-01 (estimated)
Study Completion	2025-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-07